Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]Linafexor Mass Balance Study in Healthy Subjects
NCT06098027Phase 1Completed
- Sponsor
- Cascade Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linafexor in primary biliary cholangitis (PBC), sponsored by Cascade Pharmaceuticals. Primary endpoints: Total Mass Balance, [14C] CS0159 metabolite and 5 more. Started Oct 2023; status: completed.
02
Drugs
linafexor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06098027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06098027.